Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Stocks in this Quantisnow insightHealth Care
Historical context for DMRA
Across the 6 sessions after earlier DMRA headlines, the stock closed higher 2 times and lower 4 times, with a median move of 4.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | DMRA | SPY |
|---|---|---|---|
| May 1, 2026 | Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -1.2% | +0.3% |
| Apr 24, 2026 | RBC Capital Mkts initiated coverage on Damora Therapeutics with a new price target | -2.6% | +0.8% |
| Mar 30, 2026 | Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -4.8% | -0.3% |
| Mar 25, 2026 | Evercore ISI initiated coverage on Damora Therapeutics with a new price target | +4.7% | +0.6% |
| Mar 23, 2026 | Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors | +27.1% | +1.1% |
| Mar 20, 2026 | Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights | -5.5% | -1.7% |
Keep researching DMRA
- DMRA insider tradesEvery buy and sale reported by Damora Therapeutics Inc. officers, directors and large holders.
- DMRA earnings historyPast Damora Therapeutics Inc. earnings releases, newest first.
- DMRA financial statementsRevenue, profit, cash flow and balance sheet from Damora Therapeutics Inc.'s SEC filings.
Quantisnow market dataNASDAQ
DMRA
Damora Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2020
Get push alerts for DMRA
Full DMRA profile on Quantisnow Follow DMRA and get a push notification the moment its next story breaks.